Siga

SIGA Technologies is a commercial-stage biopharmaceutical company with a critical mission to protect against high-consequence infectious disease threats, primarily orthopoxviruses. Its strategy is built on proactive preparedness and government partnerships, most successfully demonstrated by its lead product, TPOXX® (tecovirimat), which is a cornerstone of the U.S. Strategic National Stockpile and approved in multiple regions. The company has established a defensible niche in global health security, generating $139M in 2024 revenue through sales to over 30 countries, while advancing its pipeline into new indications and formulations.

Discovery and development of novel small-molecule antiviral drugs targeting specific, vulnerable pathways in viral pathogens, exemplified by TPOXX's inhibition of the conserved VP37 protein in orthopoxviruses.